CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Delaware 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86- 898-6681-1730 (China)] [CERTIFICATION OF OF THERBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THERBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:August 14, 2012 President and Chief Executive Officer cphi10qex321063012.htm 4 EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:August 14, 2012 (principal financial officer and principal accounting officer) cphi10qex322063012.htm 5 EX-32.2]

By | 2016-02-07T21:58:18+00:00 August 14th, 2012|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x June 30, 2012

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Delaware 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86- 898-6681-1730 (China)] [CERTIFICATION OF OF THERBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THERBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:August 14, 2012 President and Chief Executive Officer cphi10qex321063012.htm 4 EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:August 14, 2012 (principal financial officer and principal accounting officer) cphi10qex322063012.htm 5 EX-32.2]

By | 2016-02-07T21:59:10+00:00 August 14th, 2012|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 5 EX-32.2]

By | 2016-02-07T15:45:04+00:00 August 14th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BIOSTAR PHARMACEUTICALS, INC. RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTART SALES OF ITS GEL CAPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on July 30, 2012, after]

By | 2016-03-03T11:54:18+00:00 August 6th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS, INC. RECEIVES APPROVAL FROM XIANYANG SFDA

[BIOSTAR PHARMACEUTICALS, INC. RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTART SALES OF ITS GEL CAPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on July 30, 2012, after]

By | 2016-03-03T11:56:01+00:00 August 6th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BIOSTAR PHARMACEUTICALS, RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTARTLES OF ITS GELPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, (NASDAQ GM: BSPM) ("Biostar" or "thempany"), a-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases andnditions, today announced that on July 30, 2012, after a thorough]

By | 2016-02-07T15:46:31+00:00 August 6th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS, RECEIVES APPROVAL FROM XIANYANG SFDA TO

[BIOSTAR PHARMACEUTICALS, RECEIVES APPROVAL FROM XIANYANG SFDA TO RESTARTLES OF ITS GELPSULE DRUGS XIANYANG, China, August 3, 2012 - Biostar Pharmaceuticals, (NASDAQ GM: BSPM) ("Biostar" or "thempany"), a-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases andnditions, today announced that on July 30, 2012, after a thorough]

By | 2016-02-07T15:47:24+00:00 August 6th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

WX [WuXi PharmaTech (Cayman)] S-8: (Original Filing)

[] [WUXI PHARMATECH (CAYMAN) INC. 2007 EMPLOYEE SHARE INCENTIVE PLAN 1. PURPOSE OF PLAN Plan Company The purpose of this WuXi PharmaTech (Cayman) Inc. 2007 Employee Share Incentive Plan (this “ 2. ELIGIBILITY Eligible Person Securities Act participant Subsidiary The Administrator (as such term is defined in Section 3.1) may grant awards under this Plan only to those persons that the] [WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road Waigaoqiao Free Trade Zone July. 30, 2012 Shanghai 200131 People’s Republic of China Dear Sirs, WuXi PharmaTech (Cayman) Inc. (the “Company”) Registration Statement” Act Shares” Plan We have been asked to render this opinion in our capacity as counsel as to Cayman Islands law to the Company in connection with the Registration] [MAPLES and CALDER CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement on Form S-8 of our reports relating to the financial statements and financial statement schedule of WuXi PharmaTech (Cayman) Inc. and the effectiveness of WuXi PharmaTech (Cayman) Inc.’s internal control over financial reporting dated April 20, 2012, appearing in]

By | 2016-04-02T17:38:24+00:00 July 30th, 2012|Categories: Chinese Stocks, SEC Original, WX|Tags: , , , , , |0 Comments
Skip to toolbar